Maze Therapeutics (MAZE) Revenue (2024 - 2026)

Maze Therapeutics (MAZE) posted Revenue of $20.0 million for Q1 2026, up 113.11% sequentially from -$152.5 million in Q4 2024.

Maze Therapeutics (MAZE) Revenue (2024 - 2026) Analysis & Trends

Maze Therapeutics has reported Revenue for 2 years, with the latest figure at $20.0 million in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 114.81% YoY) and the FY2024 annual result came in at $15.0 million, changed N/A from the prior year.
Revenue improved to $20.0 million in Q1 2026 per MAZE's latest filing, from -$152.5 million in the prior quarter.
Over five years, Revenue peaked at $20.0 million in Q1 2026 and troughed at -$152.5 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Maze Therapeutics	1.51 Bn	1.51 Bn	-	-

Download Data